Fibroblast Activation Protein Inhibitor Theranostics

Shobhana Raju; Jaya Shukla; Rakesh Kumar

doi:10.1016/j.cpet.2022.03.005

Fibroblast Activation Protein Inhibitor Theranostics

PET Clin. 2022 Jul;17(3):453-464. doi: 10.1016/j.cpet.2022.03.005.

Authors

Shobhana Raju¹, Jaya Shukla², Rakesh Kumar³

Affiliations

¹ Department of Nuclear Medicine, AIIMS, New Delhi 110029, India.
² Department of Nuclear Medicine and PET, PGIMER, Chandigarh 160012, India.
³ Diagnostic Nuclear Medicine Division, Department of Nuclear Medicine, AIIMS, New Delhi 110029, India. Electronic address: rkphulia@hotmail.com.

PMID: 35717101
DOI: 10.1016/j.cpet.2022.03.005

Abstract

The evolution of the fibroblast activation protein inhibitor molecules over the past decade has brought into the forefront a novel theranostic agent that has the potential of matching the workhorse of PET/computed tomography, [fluorine-18] fluoro-2-deoxy-d-glucose (18F-FDG). It is hoped that in the next decade it can act as a complementary tracer to 18F-FDG, in providing phenotypic and biomarker information and also in directing fibroblast activation protein-targeted therapies.

Keywords: Fibroblast activation protein; Fibroblast activation protein inhibitor; PET.

Publication types

Review

MeSH terms

Fibroblasts / metabolism
Fluorodeoxyglucose F18*
Humans
Positron-Emission Tomography
Precision Medicine*
Tomography, X-Ray Computed

Substances

Fluorodeoxyglucose F18